12.07.2015 Views

Sarah Larney, Bradley Mathers and Kate Dolan Illicit drug treatment ...

Sarah Larney, Bradley Mathers and Kate Dolan Illicit drug treatment ...

Sarah Larney, Bradley Mathers and Kate Dolan Illicit drug treatment ...

SHOW MORE
SHOW LESS
  • No tags were found...

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

2.2.2 Psychiatric complicationsOngoing psychostimulant use can result in mood disturbances <strong>and</strong>/or psychosis. Patientsmust be carefully assessed for psychosis, depression <strong>and</strong> suicidal ideation <strong>and</strong> appropriatemedications prescribed. Patients with severe psychosis or suicidal ideation may requirehospitalisation.2.2.3 Experimental pharmacotherapiesStudies are underway to determine the efficacy of mirtazapine in treatingpsychostimulant withdrawal. A recent study in a criminal justice setting in Thail<strong>and</strong>found that patients treated with mirtazapine had reduced withdrawal severity scorescompared to a placebo group (Kongsakon, Papadopoulos, & Saguansiritharn, 2005).Pending further studies, mirtazapine may be a useful pharmacotherapy for use inpsychostimulant detoxification in prisons.2.3 Psychological supportPsychological support in the form of accurate information regarding withdrawalsymptoms <strong>and</strong> strategies for coping with cravings can be useful in reducing patientanxiety <strong>and</strong> preparing the patient for the withdrawal experience. Psychological support isalso valuable in cases where withdrawal symptoms continue beyond the provision ofwithdrawal medications. Providing psychological support during withdrawal adds to theeffectiveness of pharmacological <strong>treatment</strong>s (Amato et al., 2004).13

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!